Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
Handles both loading doses and most maintenance doses for concentrations of 2.5 mg/mL and above
Trials have studied retatrutide in adults with obesity (BMI 30) or overweight (BMI 27) with comorbidities
LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): preliminary results from the phase I TROPION-PanTumor01 study
As obesity-related diseases continue to pressure public health infrastructure, pharmaceuticals are exploring the potential use of these medicines in long-term chronic disease therapy
Triple-Hormone Combination Retatrutide Induces 24% Body Weight Reduction
US$ 23.69
US$ 29.61
US$ 25.44
US$ 25.94
US$ 21.08
